- Home
- CLB vs KALV Comparison
CLB vs KALV Comparison
Compare CLB & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLB | KALV |
|---|---|---|
| Founded | 1936 | N/A |
| Country | United States | United States |
| Employees | 3300 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 864.2M | 1.0B |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CLB | KALV |
|---|---|---|
| Price | $16.86 | $26.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $12.50 | ★ $32.60 |
| AVG Volume (30 Days) | 276.9K | ★ 1.0M |
| Earning Date | 04-29-2026 | 07-09-2026 |
| Dividend Yield | ★ 0.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $526,520,000.00 | $50,000,000.00 |
| Revenue This Year | N/A | $185.42 |
| Revenue Next Year | $4.75 | $59.23 |
| P/E Ratio | $26.69 | ★ N/A |
| Revenue Growth | 0.51 | ★ 495.66 |
| 52 Week Low | $9.72 | $9.83 |
| 52 Week High | $20.36 | $21.31 |
Technical Indicators
Market Signals| Indicator | CLB | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 75.45 |
| Support Level | $15.71 | $14.43 |
| Resistance Level | $17.05 | N/A |
| Average True Range (ATR) | 0.61 | 1.04 |
| MACD | 0.05 | 0.25 |
| Stochastic Oscillator | 44.70 | 99.51 |
Price Performance
Historical ComparisonAbout CLB Core Laboratories Inc.
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.